• français
    • English
  • English 
    • français
    • English
  • Login
JavaScript is disabled for your browser. Some features of this site may not work without it.
BIRD Home

Browse

This CollectionBy Issue DateAuthorsTitlesSubjectsJournals BIRDResearch centres & CollectionsBy Issue DateAuthorsTitlesSubjectsJournals

My Account

Login

Statistics

View Usage Statistics

Investigating Generic and Brand Name Pharmaceutical’s Market Shares and Prices in Tunisia

Thumbnail
View/Open
1247042577_497.pdf (311.1Kb)
Date
2008
Dewey
Marketing
Sujet
Préférences; Industrie pharmaceutique; Consommateurs et marques de commerce
JEL code
I18; D12; L65; I11
Conference name
Economic Research Forum 15th annual conference : "Equity and economic development"
Conference date
11-2008
Conference city
Caire
Conference country
Égypte
URI
https://basepub.dauphine.fr/handle/123456789/3608
Collections
  • LEDa : Publications
Metadata
Show full item record
Author
Chebbi, Houssem Eddine
Boujelbene, Younes
Ayadi, Inès
Type
Communication / Conférence
Item number of pages
14
Abstract (EN)
The purpose of this paper is to investigate how the brand name’s market shares in Tunisia are affected by generic competition during the pre-reform period of the Tunisian health insurance system following the methodological approach developed by Aronsson et al. (2001). In this study we use data for three molecules Captopril (antihypertensive) Glibenclamide (antidiabetic) and Carbamazepine (antiepileptic) from IMS Health database. The data span from the third quarter 2002 to second quarter 2007. Statistical results indicate that the impact of generic competition seems to be not different across markets (Captopril, Glibenclamide and Carbamazepine) in Tunisia. In addition, the relative price has a positive and significant effect on the change of market share of the brand name drug in Tunisia for the three active molecules. The higher the price of the brand name product relative to the average price of the generic substitutes, the smaller the decrease of market share of the brand name product. In Tunisian pharmaceutical market, brand- names charge a higher price than their generic versions and still obtain positive market shares. Thus, from a policy perspective, the large market share of higher priced brand-names relative to their generic versions is an unsatisfactory outcome taking into account that brand name drug and generics are identical products and provide similar health gains to patients.

  • Accueil Bibliothèque
  • Site de l'Université Paris-Dauphine
  • Contact
SCD Paris Dauphine - Place du Maréchal de Lattre de Tassigny 75775 Paris Cedex 16

 Content on this site is licensed under a Creative Commons 2.0 France (CC BY-NC-ND 2.0) license.